HAND2 and lung adenocarcinoma: The methylation status of HAND2-AS1 promoter was further verified using an online software DiseaseMeth 2.0 [24], which showed that HAND2-AS1 is hypermethylated in several cancers, such as bladder carcinoma, lung adenocarcinoma, pancreatic adenocarcinoma, head and neck cancers, colon carcinoma, and anal carcinoma (Supplementary Figure S1b).